Drugmaker Glenmark Pharmaceuticals has said that its prospective novel drug GBR 830, for the treatment of auto-immune diseases, is entering human trials.
The company has completed the first phase of enabling preclinical development program for GBR 830 and has filed a Phase-I clinical trial application with authorities in the Netherlands, the company said. Drug molecules are tested on human volunteers to test for safety and efficacy of the monoclonal antibody, in this case. GBR 830 targets auto-reactive T cells.